US Market Report for Orthopedic Growth Factor 2017 - MedCore

US Market Report for Orthopedic Growth Factor 2017 - MedCore

  • March 2017 •
  • 454 pages •
  • Report ID: 4759853 •
  • Format: PDF

General Report Contents
- Market Analyses include: Unit Sales, ASPs, Market Value & Growth Trends
- Market Drivers & Limiters for each chapter segment
- Competitive Analysis for each chapter segment
- Section on recent mergers & acquisitions

The U.S. market reacted strongly to public opinion on the backlash of product INFUSE® for its performance. Initially approved for spinal fusion in 2001, INFUSE® was subsequently approved for tibial fractures in 2004, then for dental operations in 2007. Lawsuits have accused Medtronic of hiding side effects and promoting unapproved use. The decline seen in unit sales in 2013 can be attributed to the controversy and lawsuits surrounding the misuse of INFUSE® for unapproved indications in the spine.

Growth factors are a group of small, soluble proteins that bind onto cell surface receptors, triggering a series of signals that regulate the body’s ability to grow, renew and heal. Due to the regenerative properties of growth factors, they have been exploited for bone healing in orthopedic applications. Since September 1, 2015, there are two main growth factor products offered in the U.S. market: INFUSE® by Medtronic and AUGMENT® by Wright Medical. Stryker’s OP-1™ which had been sold to Olympus Biotech is no longer available as Olympus Biotech ceased sales May 31, 2014. Stryker’s OP-1™ is a different form of bone morphogenic proteins (BMPs) that belong to a larger family of proteins called transforming growth factors.

Scope: 2013-2023